[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Herbolab India Pvt. Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":121},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,62,82,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100559991","a-clinical-trial-of-de-stress--snooze-gummies-in-reducing-stress-and-insomnia-disorder-100559991",false,"NCT06571331","A Clinical Trial of De-Stress & Snooze Gummies in Reducing Stress and Insomnia Disorder","A Randomized, Double Blind, Placebo-controlled, Parallel Arm Clinical Trial of De-Stress and Snooze Gummies in Reducing Stress, Insomnia Disorder, Associated Symptoms and Overall Quality of Life","Inclusion Criteria:\n\n1. Male and female participants aged 21-50 years both inclusive\n2. Suffering from self-reported mild to moderate stress on the PSS scale score less than or equal to 26\n3. Participants willing to participate in clinical trials and who have read understood and signed the informed consent form\n4. Participants diagnosed with insomnia disorder based on the Diagnostic and Statistical Manual of Mental Disorders text revision DSM-V-TR\n5. Insomnia Severity Index more than 7 and less than 21 i.e. mild to moderate\n6. Participants with a diagnosis of mild or moderate depression patient's health questionnaire PHQ-9 score of less than or equal to 14\n7. Participants with a diagnosis of mild or moderate generalized anxiety disorder GAD -7 questionnaire score of less than or equal to 10.\n\nExclusion Criteria:\n\n1. Difficulty sleeping due to a medical condition\n2. History of a neurological disorder\n3. History of bipolar disorder psychotic disorder or posttraumatic stress disorder or current psychiatric disorder that requires medication\n4. On-going depression and generalized anxiety disorder diagnosis on PHQ 9 score greater than or equal to 15 and GAD-7 score greater than or equal to 11 scales\n5. History of substance abuse or dependence\n6. History or current evidence of a clinically significant cardiovascular disorder at pre-study visit\n7. Taking certain prohibited medications\n8. Consumption of greater than 10 cigarettes a day\n9. Participants who consume greater than or equal to 120 mg\u002Fday of caffeine and are unwilling to restrict their intake throughout the study\n10. Current evidence or history of malignancy less than or equal to 5 years prior to signing informed consent\n11. Participants currently using any nutraceutical, allopathic, or ayurvedic supplement for stress or insomnia management\n12. Known hypersensitivity to any ingredients of product\n13. Pregnant or lactating women, as well as women of childbearing potential who are not using contraception or intending to conceive during the study\n14. Other conditions, which in the opinion of the investigators, makes the participant unsuitable for enrolment or could interfere with his her participation in and completion of the protocol.",true,"ALL","21 Years","50 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","The current study focuses on clinical validation of efficacy of nutraceutical product in management of sleep disorder. Improved sleep quality contributes significantly to cognitive function. With a good night's sleep, individuals often find themselves more alert, focused, and better equipped to handle complex tasks and problem-solving scenarios. This can enhance productivity at work, as well as improve the ability to engage in meaningful conversations and activities. Memory consolidation, which occurs during sleep, is also optimized, leading to better retention of information and a sharper mind.",[28,29,30],"Stress","Insomnia","Quality of Life",[28,29,30],"NOT_YET_RECRUITING","2024-08-23",{"date":35,"type":36},"2024-08-26","ACTUAL",{"date":38,"type":22},"2024-09-05",{"date":40,"type":22},"2024-12-28",{"name":42,"class":43},"Herbolab India Pvt. Ltd.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":51,"minAge":18,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":61,"locationsCount":4},"100559990","clinical-study-to-reduce-premature-ejaculation-in-healthy-adult-men-100559990","NCT06571318","Clinical Study to Reduce Premature Ejaculation in Healthy Adult Men","A Randomized, Double Blind, Placebo-controlled, Parallel Arm Clinical Trial of De-Stress and Perform Capsule in the Management of Stress-induced Premature Ejaculation in Healthy Adult Men","Inclusion Criteria:\n\n1. Male participants aged 21-50 years both inclusive suffering from a. PE or b. ED\n2. Suffering from self-reported mild to moderate stress on the PSS scale score less than or equal to 26\n3. Participant having baseline IELT of less than 2 min\n4. Participants meeting with diagnostic criteria for PEP score greater than or equal to 11\n5. Participants who have scored 11 to 25 on the Erectile Function EF domain of the International Index of Erectile Function IIEF at screening visit a subset of 15 patients only that is 5 participants from each group\n6. Participants should be in an active stable sexual relationship only married participants for the entire duration of the study\n7. Participants willing to participate in clinical trials and who have read understood and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Previous events or other severe conditions that may affect premature ejaculation\u002Ferectile dysfunction, including but not limited to spinal trauma or pelvic surgery\n2. Participants with genital anatomical deformities, including but not limited to penile deformities\n3. Participants for whom sexual activity is inadvisable because of their underlying disease status\n4. Female partners experiencing sexual dysfunction, such as painful intercourse, low libido, or other forms of sexual dysfunction, as well as pregnant individuals\n5. Presence or history of any of the following disorders\u002Fdisease within the past 3 months, that might have impact on the clinical trial as per the investigator discretion. cardiovascular, b) cerebrovascular, c) dermatological, d) gastrointestinal, e) gynaecological, f) hematological, g) hepatic, h) malignancy, i) metabolic, j) musculoskeletal, k) neurological, l) psychiatric, m) thyroid n) psychological, o) renal, p) respiratory, q) venereal, r) any other major disorders\n6. Participants that have undergone radical prostatectomy, spinal cord injury, or any other surgery of urogenital organs;\n7. Participants with history or presence of significant alcoholism or drug abuse within the past 1 year\n8. Participants with history or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco\u002Fnicotine products more than 10 times per day\n9. Any concomitant treatment that is not permissible including but not limited to (nitrates, anti-androgens, chemotherapy agents, radiotherapy, etc).\n10. Recent participation in another clinical trial or receiving some other drug during the study besides that in the protocol\n11. Known hypersensitivity to any of the ingredients of investigational product\n12. Participants concurrent use of sildenafil or other such drugs in the PDE5 inhibitor family, energy supplements, herbal or pharmaceutical aphrodisiacs, body composition enhancing agents, or other concurrent medication such as beta blockers, contraceptives, and psychotropic medications, nutraceutical, or ayurvedic supplement for stress and\u002For PE management\n13. Other conditions, which in the opinion of the investigators, makes the participant unsuitable for enrolment or could interfere with his\u002Fher participation in, and completion of the protocol.","MALE",{"count":21,"type":22},[25],"The current study focuses on clinical validation of efficacy of nutraceutical product in management of male health. In healthy adult men with induced premature ejaculation, the introduction of these nutraceuticals has been associated with notable improvements in quality of life. These supplements help them for enhanced sexual satisfaction, increased control over ejaculation, and a reduction in performance anxiety. The psychological benefits are significant, as the improvement in sexual function can lead to higher self-confidence and a more positive outlook on life.",[56,28],"Premature Ejaculation",[56,28],{"date":35,"type":36},{"date":38,"type":22},{"date":40,"type":22},{"name":42,"class":43},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":69,"targetDuration":4,"studyType":23,"phases":71,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":81,"locationsCount":4},"100559971","a-clinical-study-of-de-stress--chill-gummies-in-reducing-stress-100559971","NCT06571071","A Clinical Study of De-Stress & Chill Gummies in Reducing Stress","A Randomized, Double Blind, Placebo-controlled, Parallel Arm Clinical Trial of De-Stress & Chill Gummies in Reducing Stress and Anxiety, and Improving Mood in Adults","Inclusion Criteria:\n\n1. Male and female participants aged 21-50 years both inclusive\n2. Suffering from self-reported mild to moderate stress on the PSS scale score less than or equal to 26\n3. Participants willing to participate in clinical trials and who have read understood and signed the informed consent form\n4. No severe anxiety and depression i.e. Generalized anxiety disorder GAD score less than or equal to 10 and Patients' health questionnaire-9 PHQ-9 score less than or equal to 14\n5. A female participant who is of reproductive potential has a negative pregnancy test and agrees to use contraception throughout the study period 6 No history of substance use disorder other than the use of nicotine and recreational use of alcohol not having used for the last 14 days and consenting not to use the same during the period of the trial\n\n7\\. Willing to limit caffeine consumption while in the study.\n\nExclusion Criteria:\n\n1. Inability to perform any of the assessments required for endpoint analysis\n2. Shows signs of dementia, such as caused by Alzheimer's Disease, acquired immunodeficiency syndrome (AIDS), Creutzfeldt-Jakob disease (CJD), Lewy Bodies dementia (LBD), Cerebrovascular dementia (CVD), Progressive Supranuclear Palsy (PSP), multiple cerebral infarctions, or normal pressure hydrocephalus (NPH)\n3. Participants currently using any nutraceutical, allopathic, or ayurvedic supplement for stress management\n4. Have any other neurodegenerative diseases or seizure disorder\n5. Known hypersensitivity to investigational products\n6. Participants with a history of malignancy diagnosed within the past 5 years or currently diagnosed with malignancy\n7. Pregnant or lactating women, as well as women of childbearing potential who are not using contraception or intending to conceive during the study\n8. Sitting or resting systolic blood pressure of more than 180 mm Hg or diastolic blood pressure of more than 110 mm Hg at screening\n9. Participants with a history of substance abuse, drugs, heavy use of alcohol, and\u002For smoking within the last 5 years\n10. Serious illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the participant or preclude the successful completion of the study.",{"count":70,"type":22},72,[25],"The current study focuses on clinical validation of efficacy of nutraceutical product in reduction of stress,anxiety and improving mood in adults. Adults experiencing chronic stress and anxiety often suffer from a reduced quality of life, marked by symptoms such as irritability, fatigue, and difficulty concentrating. By integrating these gummies into their daily routine, many report noticeable improvements in their emotional and mental state. These enhancements can manifest as increased energy levels, better sleep quality, and a more balanced mood, which collectively contribute to a more positive outlook on life.",[28,74],"Anxiety",[76,74],"stress","2024-08-22",{"date":35,"type":36},{"date":38,"type":22},{"date":40,"type":22},{"name":42,"class":43},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":100,"locationsCount":4},"100559809","clinical-study-of-de-stress--happy-gut-powder-for-stress-and-indigestion-in-adults-100559809","NCT06568965","Clinical Study of De-Stress & Happy Gut Powder for Stress and Indigestion in Adults.","A Randomized, Double-blind, Placebo-controlled, Parallel Arm Clinical Trial of De-Stress and Happy Gut Powder in Relieving Stress and Functional Dyspepsia Symptoms in Adults.","Inclusion Criteria:\n\n1. Male and female participants aged 21-50 years both inclusive\n2. Suffering from self-reported mild to moderate stress on the PSS scale score less than or equal to 26\n3. Participants willing to participate in clinical trials and who have read understood and signed the informed consent form\n4. No severe anxiety and depression i.e. Generalized anxiety disorder GAD score less than or equal to 10 and Patients' health questionnaire-9 PHQ-9 score less than or equal to 14\n5. Diagnosis of functional dyspepsia\u002Fnon-ulcer dyspepsia by fulfilling Rome-III criteria\n6. Participant should be suffering with at least 4 or more symptoms mentioned below and with a total symptom score of 20 or more based on a 7-point Likert scale (a) Upper abdominal fullness (b) Upper abdominal pain (c) Belching (d) Bloating (e) Early satiety (f) Nausea (g) Vomiting (h) Regurgitation (i) Heartburn (j) Loss of appetite\n\nExclusion Criteria:\n\n1. Inability to perform any of the assessments required for endpoint analysis\n2. Known hypersensitivity to investigational products\n3. Participants with a history of substance abuse, drugs, heavy use of alcohol, and\u002For smoking within last 5 years\n4. Advanced chronic illness that would impair follow-up or monitoring\n5. Participants who have used dietary supplements, medications, such as oral\u002FIV antibiotics or probiotics, or supplements known to affect hunger, satiety, appetite, or gut microbiome within three months prior to recruitment. Additionally, individuals currently using nutraceuticals, allopathic, or ayurvedic supplements for stress and or gastrointestinal health management;\n6. Participants suffering from abdominal obesity that is waist circumference of more than 80 cm in females and of more than 90 cm in male;\n7. Pregnant or lactating women, as well as women of childbearing potential who are not using contraception or intending to conceive during the study\n8. Participants with current or past diagnoses of peptic ulcer disease, gastroesophageal reflux disorder (GERD), or irritable bowel syndrome (IBS), as well as those who have undergone surgery related to these conditions\n9. Have any other neurodegenerative diseases, mental illness or dementia\n10. Any other clinical condition in the judgment of investigator finds the study participation unsuitable for the participant.",{"count":90,"type":22},81,[25],"The current study focuses on clinical validation of efficacy of nutraceutical product in relieving stress and functional dyspepsia symptoms in adults for gut health. The effect of these nutraceuticals not only targets the physical symptoms but also enhances overall well-being. Improved digestive health leads to better nutrient absorption, which is essential for energy levels and immune function. Reduced stress levels contribute to better sleep quality, cognitive function, and emotional stability.",[28,94,95],"Dyspepsia","Indigestion",[76,94,95],{"date":33,"type":36},{"date":38,"type":22},{"date":40,"type":22},{"name":42,"class":43},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":16,"sex":17,"minAge":108,"maxAge":19,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":119,"leadSponsor":120,"locationsCount":4},"100559877","a-clinical-trial-of-de-stress-and-focus-capsule-in-the-management-of-stress-100559877","NCT06569849","A Clinical Trial of De-stress and Focus Capsule in the Management of Stress.","A Randomized, Double-blind, Placebo-controlled, Parallel Arm Clinical Trial of De-Stress and Focus Capsule in the Management of Stress, Mental Alertness, Fatigue, and Anxiety","Inclusion Criteria:\n\n1. Male and female participants aged 18-50 years both inclusive\n2. Suffering from self-reported mild to moderate stress on the PSS scale score less than or equal to 26\n3. Scoring 18-26 on the Montreal Cognitive Assessment MoCA\n4. No or minimal impairment in activities of daily living: scoring less than 9 on the Functional Activities Questionnaire FAQ\n5. Participants willing to participate in clinical trials and who have read understood and signed the informed consent form\n6. No severe anxiety and depression on GAD and PHQ-9 scales\n7. Able to complete the cognitive assessment tests\n\nExclusion Criteria:\n\n1. Inability to perform any of the assessments required for endpoint analysis\n2. Shows signs of Dementia, such as caused by Alzheimer's Disease, acquired immunodeficiency syndrome AIDS, Creutzfeldt-Jakob disease, Lewy Bodies dementia LBD, Cerebrovascular dementia CVD, Progressive Supranuclear Palsy PSP, multiple cerebral infarctions, or normal pressure hydrocephalus NPH, cardiac disease or endocrine disease\n3. Have any other neurodegenerative diseases\n4. History of a seizure disorder\n5. Known hypersensitivity to investigational products\n6. Participants with a history of malignancy diagnosed within the past 5 years or currently diagnosed with malignancy\n7. Sitting or resting systolic blood pressure of more than 180 mm Hg or diastolic blood pressure of more than 110 mm Hg at Screening.\n8. Participants with a history of substance abuse, drugs, heavy use of alcohol, and\u002For smoking within the last 5 years\n9. Participants currently using medications and or supplements that could have cognitive or mood effects including but not limited to nutraceutical, allopathic, ayurvedic herbal extract or supplement\n10. Pregnant or lactating women, as well as women of childbearing potential who are not using contraception or intending to conceive during the study\n11. Serious illness or any other condition that, in the opinion of the investigator may compromise the safety or compliance of the patient or preclude the successful completion of the study","18 Years",{"count":21,"type":22},[25],"The current study focuses in clinical validation of the efficacy of nutraceutical product in the management of mental focus and cognition. The benefits of these nutraceuticals extend beyond mere cognitive enhancement. Improved mental focus can lead to increased productivity and efficiency in both personal and professional settings. Individuals who struggle with attention deficits or cognitive fog may find that these supplements help them maintain a sharper and more consistent level of mental clarity. This can translate to better performance at work, as well as improved ability to manage daily tasks and responsibilities.",[74,28,113],"Stuporous",[76,115,116,74],"Mental alertness","Fatigue",{"date":35,"type":36},{"date":38,"type":22},{"date":40,"type":22},{"name":42,"class":43},""]